Neurotech International
- Home ›
- AU ›
- Healthcare
Neurotech International Limited engages in the research, design, development, and manufacture of medical devices in Australia. The last earnings update was 51 days ago. More info.
Add to Portfolio Compare Print
- Neurotech International has significant price volatility in the past 3 months.
NTI Share Price and Events
7 Day Returns
1 Year Returns
NTI Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Neurotech International (NTI) | 228.6% | 4.5% | - | -88.5% | - | - |
| AU Medical Equipment | 4.1% | 0.9% | 0.8% | -3.3% | 38.7% | 103.7% |
| AU Market | -0% | 1.5% | 6.5% | 4.9% | 18.2% | 4.8% |
1 Year Return vs Industry and Market
- NTI underperformed the Medical Equipment industry which returned -3.3% over the past year.
- NTI underperformed the Market in Australia which returned 4.9% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Neurotech International. This is due to cash flow or dividend data being unavailable. The share price is A$0.023.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Neurotech International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Neurotech International's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.04 |
| ASX:NTI Share Price ** | ASX (2019-04-18) in AUD | A$0.02 |
| Australia Medical Equipment Industry PE Ratio | Median Figure of 8 Publicly-Listed Medical Equipment Companies | 33.38x |
| Australia Market PE Ratio | Median Figure of 545 Publicly-Listed Companies | 16.18x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Neurotech International.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:NTI Share Price ÷ EPS (both in AUD) = 0.02 ÷ -0.04 |
-0.65x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Neurotech International is loss making, we can't compare its value to the AU Medical Equipment industry average.
- Neurotech International is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Neurotech International's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -0.65x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| Oceania Medical Equipment Industry PEG Ratio | Median Figure of 5 Publicly-Listed Medical Equipment Companies | 2.62x |
| Australia Market PEG Ratio | Median Figure of 360 Publicly-Listed Companies | 1.37x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Neurotech International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Neurotech International's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.02 |
| ASX:NTI Share Price * | ASX (2019-04-18) in AUD | A$0.02 |
| Australia Medical Equipment Industry PB Ratio | Median Figure of 30 Publicly-Listed Medical Equipment Companies | 2.72x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.67x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:NTI Share Price ÷ Book Value per Share (both in AUD) = 0.02 ÷ 0.02 |
0.98x |
* Primary Listing of Neurotech International.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Neurotech International is good value based on assets compared to the AU Medical Equipment industry average.
Value checks
We assess Neurotech International's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Neurotech International has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Neurotech International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Neurotech International's earnings growth to the Australia market average as no estimate data is available.
- Unable to compare Neurotech International's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Australia Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 13.2% |
| Australia Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 8.4% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.5% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 0 | -3 | -4 |
| 2018-09-30 | 0 | -3 | -4 |
| 2018-06-30 | 0 | -3 | -4 |
| 2018-03-31 | 0 | -3 | -4 |
| 2017-12-31 | 0 | -3 | -4 |
| 2017-09-30 | 0 | -3 | -4 |
| 2017-06-30 | 0 | -3 | -4 |
| 2016-12-31 | 0 | -3 | -4 |
| 2016-09-30 | 0 | -2 | -4 |
| 2016-06-30 | 0 | -2 | -3 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Neurotech International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.04 |
| 2018-09-30 | -0.04 |
| 2018-06-30 | -0.04 |
| 2018-03-31 | -0.04 |
| 2017-12-31 | -0.04 |
| 2017-09-30 | -0.05 |
| 2017-06-30 | -0.05 |
| 2016-12-31 | -0.09 |
| 2016-09-30 | -0.08 |
| 2016-06-30 | -0.08 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Neurotech International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Neurotech International's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Neurotech International has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Neurotech International performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Neurotech International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
- Unable to compare Neurotech International's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Neurotech International's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Neurotech International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 0.19 | -3.84 | 2.53 | 0.30 |
| 2018-09-30 | 0.11 | -3.91 | 2.57 | 0.29 |
| 2018-06-30 | 0.03 | -3.99 | 2.60 | 0.29 |
| 2018-03-31 | 0.05 | -3.93 | 2.57 | 0.28 |
| 2017-12-31 | 0.08 | -3.86 | 2.54 | 0.26 |
| 2017-09-30 | 0.08 | -3.95 | 2.71 | 0.25 |
| 2017-06-30 | 0.09 | -4.03 | 2.89 | 0.24 |
| 2016-12-31 | 0.17 | -4.29 | 3.43 | 0.06 |
| 2016-09-30 | 0.19 | -3.54 | 2.80 | 0.05 |
| 2016-06-30 | 0.21 | -2.79 | 2.18 | 0.03 |
| 2015-12-31 | 0.22 | -0.84 | 0.69 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Neurotech International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Neurotech International has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Neurotech International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Neurotech International's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Neurotech International has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Neurotech International's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Neurotech International's finances.
The net worth of a company is the difference between its assets and liabilities.
- Neurotech International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Neurotech International has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 28.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Neurotech International Company Filings, last reported 3 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 2.56 | 0.03 | 0.45 |
| 2018-09-30 | 2.56 | 0.03 | 0.45 |
| 2018-06-30 | 4.23 | 0.03 | 2.21 |
| 2018-03-31 | 4.23 | 0.03 | 2.21 |
| 2017-12-31 | 6.20 | 0.36 | 4.53 |
| 2017-09-30 | 6.20 | 0.36 | 4.53 |
| 2017-06-30 | 4.30 | 0.37 | 2.64 |
| 2016-12-31 | 6.03 | 0.47 | 4.58 |
| 2016-09-30 | 6.03 | 0.47 | 4.58 |
| 2016-06-30 | 1.47 | 0.95 | 1.01 |
| 2015-12-31 | 1.29 | 1.78 | 1.88 |
- Neurotech International's level of debt (1.3%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Neurotech International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Neurotech International has less than a year of cash runway based on current free cash flow.
- Neurotech International has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.3% each year.
Financial health checks
We assess Neurotech International's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Neurotech International has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Neurotech International's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Neurotech International
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Neurotech International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Neurotech International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Oceania Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 5 Stocks | 1.7% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 417 Stocks | 4.3% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.5% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Neurotech International has not reported any payouts.
- Unable to verify if Neurotech International's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Neurotech International's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Neurotech International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Neurotech International has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | A$106,126 |
| AGE | 54 |
| TENURE AS CEO | 0.4 years |
CEO Bio
Mr. Peter James Lawrence Griffiths has been the Chief Executive Officer and Managing Director at Neurotech International Limited since November 26, 2018. Mr. Griffiths a Senior Advisor at Bridge Growth Partners, LLC since January, 2018. He also served as a Member of Technology Advisory Board at Neurotech International Limited since joining on January 21, 2015. Mr. Griffiths serves as Deputy Chairman at Neurotech International Limited and it’s a Director since May 2016. He has been a Director of Accedian Networks Inc. since June 06, 2017. He has been a Director of Martin Dawes Analytics since September 16, 2013, Lavastorm Analytics AB since September 2013 and Lavastorm Analytics, Inc. since September 16, 2013. He serves on the board of BackOffice Associates. He serves on the Board of Trustees of the Anita Borg Institute. He served as Executive Vice President and Group Executive of Enterprise Solutions & Technology Group at CA, Inc. (alternate name CA Technologies) from February 2012 to May 2014. Mr. Griffiths managed a broad portfolio of IT management and security products for enterprise and growth markets. As Executive Vice President and Group Executive at CA Technologies, he delivered business growth through new product development and a targeted M&A strategy and also led the transition to Mobile, Cloud and DevOps with the CA Technologies Innovation Center. He served as an Executive Vice President of Technology and Development Group at CA Technologies since May 2011. In his role at CA Technologies, he was responsible for investment and strategy across its broad portfolio of products and solutions for enterprise and growth markets, including leading five business units which drove CA Technologies’ leadership in IT Management Cloud, DevOps and Security. He joined CA Technologies from IBM, where for the past two years he served as a Vice President of Worldwide Research and Development Business, Analytics and Applications. At IBM, he also served as a Vice President of Products, IBM Cognos Software. He served as a Senior Vice President of Products at Cognos Espana. In his role at IBM, where he served as Vice President of WW Business Analytics and Applications Development where he was responsible for building the Business Analytics division within IBM Software Group, including the acquisition and integration of SPSS, Clarity and OpenPages. Peter has also held positions in management consulting and in the financial services industry – including as design consultant at Apple Computer, Vodafone and Fidessa. Mr. Griffiths has more than 20 years of senior level leadership experience in software and data analytics with CA Technologies, IBM and Cognos, as well as experience in management consulting and financial services. He served as a Senior Vice President of Products for Cognos ULC since April 2002. He served as Senior Vice President of Research and Development at Cognos ULC from February 2002 to April 2002; Vice President of Research and Development from January 2001 to February 2002 and its Vice President of Decision Platform from June 2000 to January 2001. Prior to joining Cognos in 1998, he co-founded Relational Matters and served as its Chief Executive Officer. Mr. Griffiths earned a Bachelor of Science degree in Electronic Engineering with 1st Class Honors from Brighton University in England.
CEO Compensation
- Peter James's compensation has increased whilst company is loss making.
- Peter James's remuneration is lower than average for companies of similar size in Australia.
Management Team
Peter James Griffiths
Deputy Chairman
A$106K
54
0.4 yrs
Emanuela Russo
Chief Scientific Officer & Member of Scientific Advisory Board
0.5 yrs
Fleur Hudson
Company Secretary
Board of Directors
Peter James Griffiths
Deputy Chairman
A$106K
54
Emanuela Russo
Chief Scientific Officer & Member of Scientific Advisory Board
David Cantor
Chairman of Scientific Advisory Board & Non-Executive Director
Tanju Surmeli
Member of Scientific Advisory Board
0.5 yrs
Evian Gordon
Member of Scientific Advisory Board
0.5 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 28. Feb 19 | Buy | Pyxis Holdings Pty Ltd | Company | 25. Feb 19 | 25. Feb 19 | 3,749,999 | A$0.03 | A$112,500 | ||
| 12. Nov 18 | Sell | Adrian Trevisan | Individual | 09. Nov 18 | 09. Nov 18 | -190,832 | A$0.07 | A$-12,658 | ||
| 19. Aug 18 | Sell | Adrian Trevisan | Individual | 08. Aug 18 | 16. Aug 18 | -243,807 | A$0.18 | A$-38,162 | ||
| 27. Jun 18 | Buy | SG Hiscock & Company Ltd. | Company | 29. Jan 18 | 25. Jun 18 | 2,500,000 | A$0.22 | A$534,159 | ||
Management checks
We assess Neurotech International's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Neurotech International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Does Neurotech International Limited (ASX:NTI) Have A Particularly Volatile Share Price?
Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Simply Wall St - – Full articleCould The Neurotech International Limited (ASX:NTI) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Neurotech International Limited (ASX:NTI) have power over the company. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of AU$5.3m, Neurotech International is a small cap stock, so it might not be well known by many institutional investors.
Simply Wall St - – Full articleWhat Kind Of Shareholders Own Neurotech International Limited (ASX:NTI)?
Every investor in Neurotech International Limited (ASX:NTI) should be aware of the most powerful shareholder groups. … Neurotech International is a smaller company with a market capitalization of AU$11m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company
Simply Wall St - – Full articleWhat does Neurotech International Limited's (ASX:NTI) Balance Sheet Tell Us About Its Future?
Investors are always looking for growth in small-cap stocks like Neurotech International Limited (ASX:NTI), with a market cap of AU$13.08m. … However, an important fact which most ignore is: how financially healthy is the business?
Simply Wall St - – Full articleIs Neurotech International Limited's (ASX:NTI) Balance Sheet A Threat To Its Future?
With this debt payback, the current cash and short-term investment levels stands at AU$2.64M for investing into the business. … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … Investors' risk associated with debt is virtually non-existent with NTI, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: Although NTI’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.
Simply Wall St - – Full articleHow Did Neurotech International Limited's (ASX:NTI) Earnings Growth Stack Up Against The Industry?
Below, I will assess Neurotech International Limited's (ASX:NTI) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … View our latest analysis for Neurotech International Did NTI's recent earnings growth beat the long-term trend and the industry? … For Neurotech International, its latest earnings (trailing twelve month) is -AU$3.86M, which, against the prior year's figure, has become less negative.
Simply Wall St - – Full articleHow Should Investors React To Neurotech International Limited's (ASX:NTI) CEO Pay?
Recently, NTI delivered negative earnings of -AU$3.86M. … As profits are moving up and up, CEO pay should represent Storf's value creation for shareholders. … Normally I would look at market cap and earnings as a proxy for performance, however, NTI's negative earnings reduces the effectiveness of this method.
Simply Wall St - – Full articleWhat Does Neurotech International Limited's (ASX:NTI) Ownership Structure Look Like?
See our latest analysis for Neurotech International ASX:NTI Ownership_summary Feb 26th 18 Institutional Ownership Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in NTI need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.
Simply Wall St - – Full articleWhen Will Neurotech International Limited (ASX:NTI) Run Out Of Money?
Looking at Neurotech International’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … ASX:NTI Income Statement Feb 15th 18 When will Neurotech International need to raise more cash? … Not surprisingly, if Neurotech International continues to ramp up expenditure at this rate for the upcoming year, it’ll likely need to come to market within the next few months, given the its current level of cash reserves.
Simply Wall St - – Full articleIs Neurotech International Limited's (ASX:NTI) Balance Sheet Strong Enough To Weather A Storm?
NTI has shrunken its total debt levels in the last twelve months, from AU$945.61K to AU$374.80K – this includes both the current and long-term debt. … Moving onto cash from operations, its operating cash flow is not yet significant enough to calculate a meaningful cash-to-debt ratio, indicating that operational efficiency is something we’d need to take a look at. … Investors' risk associated with debt is virtually non-existent with NTI, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: Although NTI’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.
Simply Wall St - – Full articleCompany Info
Description
Neurotech International Limited engages in the research, design, development, and manufacture of medical devices in Australia. Its product is Mente Autism, a portable electroencephalogram medical device that uses neurofeedback to help relax the minds of children with autism spectrum disorder. The company focuses on developing neuro-stimulation and neuro-diagnostic solutions that enable medical practitioners to monitor and play an active role in home-based therapies. It also engages in executing medical research projects and developing technological devices; and publishing, registering, and maintaining intellectual property. The company also focuses on establishing new markets in the United Kingdom, France, and Spain. Neurotech International Limited was incorporated in 2016 and is based in Perth, Australia.
Details
| Name: | Neurotech International Limited |
| NTI | |
| Exchange: | ASX |
| Founded: | 2016 |
| A$3,122,108 | |
| 135,743,869 | |
| Website: | http://www.neurotechinternational.com |
| Address: |
Neurotech International Limited 191 St Georges Terrace, Level 14, Perth, Western Australia, 6000, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | NTI | Ordinary Shares | Australian Securities Exchange | AU | AUD | 04. Nov 2016 | |
| OTCPK | NTIL.F | Ordinary Shares | Pink Sheets LLC | US | USD | 04. Nov 2016 | |
| CHIA | NTI | Ordinary Shares | Chi-X Australia | AU | AUD | 04. Nov 2016 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/20 10:35 |
| End of day share price update: | 2019/04/18 00:00 |
| Last earnings filing: | 2019/02/28 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
